Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Trial Status: enrolling by invitation
This is an open-label, multicenter, extension study to evaluate the long-term safety and efficacy of BeiGene investigational drugs in participants with advanced malignancies who participated in a prior BeiGene-sponsored clinical study (parent study).